Welcome to our dedicated page for Cumberland Pharmaceuticals news (Ticker: CPIX), a resource for investors and traders seeking the latest updates and insights on Cumberland Pharmaceuticals stock.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) provides specialty pharmaceutical solutions for critical care and underserved medical needs. This news hub offers investors and healthcare professionals verified updates on the company's FDA-approved therapies, clinical developments, and strategic initiatives.
Access timely reports on product approvals, clinical trial milestones, and corporate partnerships across Cumberland's core therapeutic areas: hospital acute care, oncology support, gastroenterology treatments, and rare disease therapies. Our curated news collection enables informed decision-making through coverage of financial results, regulatory submissions, and market expansion efforts.
Key updates include developments for Cumberland's Ifetroban clinical program targeting rare conditions, international distribution agreements, and innovations in pain management solutions like Caldolor®. All content undergoes strict verification to ensure accuracy and relevance for stakeholders.
Bookmark this page for centralized access to CPIX's latest pharmaceutical advancements and corporate announcements. Check regularly for essential updates impacting the specialty medicine sector.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported a 26.5% increase in net revenues to $10.5 million for Q1 2021. The company also generated an additional $500,000 from divested product rights. Key products contributed significantly, with Vibativ® earning $5.1 million. Operating expenses rose to $10.9 million, influenced by higher costs from Vibativ sales. Net income was $0.2 million, representing a turnaround from a loss of $1.1 million the previous year. The financial position included $93 million in total assets and $47 million in shareholders' equity.
Cumberland Pharmaceuticals (NASDAQ: CPIX) will release its Q1 2021 financial results and company update on May 11, 2021, post-market. A conference call will follow at 4:30 p.m. ET. The company focuses on high-quality prescription brands for hospital acute care and gastroenterology. Its FDA-approved product portfolio includes Acetadote, Caldolor, Kristalose, Omeclamox-Pak, Vaprisol, Vibativ, and RediTrex. The firm is also advancing Phase II clinical programs for ifetroban targeting various diseases.
Cumberland Pharmaceuticals Inc. (CPIX) reported a strong performance for Q4 and full-year 2020, highlighting net revenues of $10.3 million in Q4, a 10% year-over-year increase, and totals of $37.4 million for the year, up 9% from 2019. The company also recognized $3.2 million in revenue from divested product rights. Total assets stood at $96.5 million, with cash and investments of $24.8 million. The firm launched new formulations for its Caldolor product, helped hospitals during the pandemic, and plans to expand its RediTrex line in 2021.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) will announce its fourth quarter and annual 2020 financial results after the market closes on March 9, 2021. A conference call will take place the same day at 4:30 p.m. Eastern Time to discuss these results. The company focuses on specialty pharmaceuticals, offering several FDA-approved products that target acute care, gastroenterology, and oncology markets. Additionally, Cumberland has ongoing Phase II clinical programs for its ifetroban product candidates aimed at treating conditions like Duchenne Muscular Dystrophy.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced the launch of RediTrex® (methotrexate) injection, a pre-filled syringe system aimed at improving the ease and accuracy of methotrexate administration for patients with arthritis and psoriasis. RediTrex is FDA approved for severe rheumatoid arthritis and psoriasis patients who struggle with oral methotrexate. It features a retractable needle and user-friendly design, reducing pain and confusion compared to existing options. The launch is slated for two phases, beginning with select centers and expanding nationally in Q1 2021.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported third quarter 2020 net revenues of $9.3 million, up from $6.9 million year-over-year. The firm also recorded $750,000 from divested product rights. Total assets stood at $96 million with $27 million in cash. The company has launched new initiatives including the FDA-approved RediTrex and expanded use of Vibativ for COVID-19 patients. However, net income for Q3 was a loss of $(0.5) million or $(0.03) per share, a slight improvement from $(2.0) million in the previous year.
Cumberland Pharmaceuticals (NASDAQ: CPIX) will announce its third quarter 2020 financial results on Nov. 10, 2020, after market close. A conference call, including a live webcast, is scheduled for the same day at 4:30 p.m. ET. The company develops and commercializes prescription brands for acute care, gastroenterology, and oncology. Its FDA-approved products include Acetadote and Kristalose, among others. Currently, Cumberland is conducting Phase II clinical trials for its ifetroban candidates targeting multiple diseases.
Cumberland Pharmaceuticals (NASDAQ: CPIX) announced results from a review of clinical studies on Caldolor® (ibuprofen) Injection published in Clinical Therapeutics. The review included 1,062 adult patients and found that Caldolor leads to a quicker plasma concentration, enhances postoperative recovery, and reduces opioid and over-the-counter medication use. The study supports the incorporation of Caldolor into Enhanced Recovery After Surgery protocols. CEO A.J. Kazimi emphasized its role in reducing opioid use amid ongoing efforts to address opioid consumption in healthcare.
Cumberland Pharmaceuticals (NASDAQ: CPIX) reported second quarter 2020 net revenues of $9.6 million from ongoing operations, up from $9.4 million year-over-year. Total revenues were $10.3 million, boosted by $750,000 from divested product rights. The Company's financial position showed $97.5 million in total assets, $49.1 million in liabilities, and $48.5 million in shareholders' equity. Net income for Q2 was a loss of $(0.9) million, equating to $(0.06) per share, while adjusted earnings improved to $1.2 million or $0.08 per diluted share. Cumberland continued to support healthcare during COVID-19 with product supply initiatives.
Cumberland Pharmaceuticals Inc. (CPIX) will release its second quarter 2020 financial results and company update on August 11, 2020, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results. The company focuses on developing and commercializing prescription brands in hospital acute care, gastroenterology, and oncology via targeted sales forces. Their FDA-approved products include Acetadote, Caldolor, Kristalose, and more, with ongoing Phase II programs for ifetroban in DMD, SSc, and AERD.
FAQ
What is the current stock price of Cumberland Pharmaceuticals (CPIX)?
What is the market cap of Cumberland Pharmaceuticals (CPIX)?
